Monitoring of global alerts for thirteen medicines in the period 2014-2020

Fernanda Rojas Salas; Sebastián Arguedas Chacón Sebastián; Raquel Arguedas Herrera; José Antonio Madrigal Elizondo; Mauricio Villegas Campos

doi:10.30574/gscbps.2020.13.2.0316

Authors

Fernanda Rojas Salas Pharmacy School, University of Costa Rica, San José, Costa Rica.
Sebastián Arguedas Chacón Sebastián Pharmacy School, University of Costa Rica, San José, Costa Rica.
Raquel Arguedas Herrera Pharmacy School, University of Costa Rica, San José, Costa Rica.
José Antonio Madrigal Elizondo Pharmacy School, University of Costa Rica, San José, Costa Rica.
Mauricio Villegas Campos Pharmacy School, University of Costa Rica, San José, Costa Rica.

DOI:

https://doi.org/10.30574/gscbps.2020.13.2.0316

Keywords:

Pharmacovigilance, Alerts, Measures, Costa Rica, Medicines

Abstract

Pharmacovigilance is based on the need to monitor and prevent possible problems caused by medications. Once national and international entities identify a problem related to medications, they issue alerts directed at health professionals, patients and the general population. In this research, national and international alerts were reviewed from 2014 to 2020, of thirteen drugs used in the treatment of common, disabling and/or fatal diseases that affect a large part of the Costa Rican population, taking alerts issued in pharmacovigilance centers databases worldwide. Health alerts show the identification of a problem and communicate the action taken by the regulatory body, which varies according to the severity of the problem. In Costa Rica, health alerts issued about drug-related effects are based on alerts issued by international regulatory bodies such as WHO and FDA, in addition to this, the Costa Rican Ministry of Health adapts the information from these alerts to the Costa Rican population. However, of the ten alerts analyzed, four were not issued in Costa Rica.

Metrics

Metrics Loading ...

References

Ministerio de Salud Costa Rica. Farmacovigilancia [Internet]. Costa Rica: Ministerio de Salud; ©2016. Available from https://www.ministeriodesalud.go.cr/index.php/regulacion-de-la-salud/farmacovigilancia

Valsecia M. Farmacovigilancia y Mecanismos de Reacciones Adversas a Medicamentos [Internet]. Argentina: Universidad Nacional del Nordeste; n.d. https://med.unne.edu.ar/sitio/multimedia/imagenes/ckfinder/files/files/13_farmacovigi.pdf

Shibbiru T, Tadesse F. Adverse Drug Reactions: An Overview. J. Journal of Medicine, Physiology and Biophysics. 2016; 9 (23): 7-14.

Coleman JJ, Pontefract SK. Adverse drug reactions. Clinical Medicine Journal. 2016; 16 (5): 481–485.

Payne R, Slight S, Franklin BD, Avery AJ. World Health Organization. World Health Organization, Department of Service Delivery and Safety, Medication errors. 2016.

Aronson JK. Medication errors. definitions and classification. British Journal of Clinical Pharmacology. 2009; 67: 599–604.

Williams DJP. Medication errors. The Journal of the Royal College of Physicians of Edinburgh. 2007; 37(4): 343-346.

World Health Organization. Substandard and falsified medical products [Internet].Western Pacific Union: World Health Organization. ©2020. Available from https://www.who.int/westernpacific/health-topics/substandard-and-falsified-medical-products

Li R, Curtain C, Bereznicki L, Zaidi STR. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. International Journal of Clinical Pharmacy. 2018; 40: 878–889.

Van Grootheest AC, De Jong-van den Berg LW. The role of hospital and community pharmacists in pharmacovigilance. Research in Social and Administrative Pharmacy. 2005; 1(1): 126–133.

World Health Organization. The Importance of Pharmacovigilance: safety monitoring of medicinal products [Internet]. United Kingdom: World Health Organization. ©2002. Available from https://apps.who.int/iris/handle/10665/42493.

Cuevas IE. Presente y futuro de la farmacovigilancia en la Industria Farmacéutica. Vaccimotor. 2007; 16(6): 20-25.

Jeetu G, Anusha G. Pharmacovigilance: A Worldwide Master Key for Drug Safety Monitoring. Journal of Young Pharmacists. 2010; 2(3):315–320.

Procuraduría General de la República. Reglamento del Sistema Nacional de Farmacovigilancia [Internet]. Costa Rica: Procuraduría General de la República; ©2009. Available from http://www.pgrweb.go.cr/scij/Busqueda/Normativa/Normas/nrm_texto_completo.aspx?param1=NRTC&nValor1=1&nValor2=65500&nValor3=76559&strTipM=TC

Ministerio de Salud Costa Rica. Cancelación de Registro Sanitario y Retiro del Mercado de Lorcaserina [Internet]. Costa Rica: Ministerio de Salud; ©2020. Available from https://www.ministeriodesalud.go.cr/index.php/centro-de-prensa/noticias/741-noticias-2020/1587-centro-nacional-de-farmacovigilancia-nota-informativa-01-20-cancelacion-de-registro-sanitario-y-retiro-del-mercado-de-lorcaserina

Food and Drug Administration. FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market [Internet]. United States of America: Food and Drug Administration; ©2020. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market

Agência Nacional de Vigilância Sanitária. Anvisa a gerência de farmacovigilância alerta para o risco potencial de ocorrência de neoplasias com o uso do medicamento belviq® (lorcasserina) [Internet]. Brasil: Agência Nacional de Vigilância Sanitária; ©2020. Available from http://portal.anvisa.gov.br/informacoes-tecnicas13/-/asset_publisher/WvKKx2fhdjM2/content/a-gerencia-de-farmacovigilancia-alerta-para-o-risco-potencial-de-ocorrencia-de-neoplasias-com-o-uso-do-medicamento-belviq-lorcasserina-/33868?p_p_auth=BOttB4WI&inheritRedirect=false&redirect=http%3A%2F%2Fportal.anvisa.gov.br%2Finformacoes-tecnicas13%3Fp_p_auth%3DBOttB4WI%26p_p_id%3D101_INSTANCE_WvKKx2fhdjM2%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3D_118_INSTANCE_EikhC3EOkiIn__column-1%26p_p_col_pos%3D1%26p_p_col_count%3D3

Food and Drug Administration. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)[Internet]. United States of America: Food and Drug Administration; ©2019. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontinhttps://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin

Medicines & Healthcare products Regulatory Agency. Pregabalin and gabapentin to be controlled as class C drugs[Internet]. United Kingdom: Medicines & Healthcare productsRegulatory Agency; ©2018. Available from https://www.gov.uk/government/news/pregabalin-and-gabapentin-to-be-controlled-as-class-c-drugs

Medicines & Healthcare products Regulatory Agency. Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy [Internet]. United Kingdom: Medicines & Healthcare products Regulatory Agency; ©2020. Available from https://www.gov.uk/drug-safety-update/ondansetron-small-increased-risk-of-oral-clefts-following-use-in-the-first-12-weeks-of-pregnancy.

Ministerio de Salud Costa Rica. Nota Informativa 02-19. Nueva Información de Seguridad para Ondansetrón [Internet]. Costa Rica: Ministerio de Salud; ©2019. Available from https://www.ministeriodesalud.go.cr/index.php/consulta-de-alertas-de-seguridad/4463-14-de-octubre-de-2019-nota-informativa-02-19-nueva-informacion-de-seguridad-para-ondansetron/file.

Therapeutic Goods Administration. Ranitidine. Updates- Contamination with N-nitrosodimethylamine [Internet]. Australia: Department of Health; ©2020. Available from https://www.tga.gov.au/alert/ranitidine-0

Ministerio de Salud Costa Rica. Alerta Sanitaria: Retiro del mercado de medicamentos que contienen ranitidina vía oral [Internet]. Costa Rica: Ministerio de Salud; ©2019. Available from https://www.ministeriodesalud.go.cr/index.php/noticias/noticias-2019/1487-alerta-sanitaria-retiro-del-mercado-de-medicamentos-que-contienen.

Food and Drug Administration. FDA News Release: La FDA anuncia el retiro voluntario del mercado de las cápsulas de ranitidina Sandoz, tras detectarse una impureza [Internet]. United States of America: Food and Drug Administration; ©2019. Available from https://www.fda.gov/news-events/press-announcements/la-fda-anuncia-el-retiro-voluntario-del-mercado-de-las-capsulas-de-ranitidina-sandoz-tras-detectarse.

Instituto Nacional de Vigilancia de Medicamentos y Alimentos. ALERTA SANITARIA: Zantac jarabe lotes 1728200002 y 1726100008[Internet]. Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos; ©2019. Available from https://app.invima.gov.co/alertas/ckfinder/userfiles/files/ALERTAS%20SANITARIAS/medicamentos_pbiologicos/2019/Octubre/Alerta%20No_%20%23149-2019%20-%20Zantac%20jarabe%20lotes%201728200002%20y%201726100008%20.pdf

Ministerio de Salud Costa Rica. Nueva información de seguridad con el uso del principio activo Pioglitazona [Internet]. Costa Rica: Ministerio de Salud; ©2017. Available from https://www.ministeriodesalud.go.cr/index.php/consulta-de-alertas-de-seguridad/3193-11-de-enero-de-2017-informacion-de-seguridad-con-el-uso-del-principio-activo-pioglitazona/file.

Food and Drug Administration. FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer [Internet]. United States of America: Food and Drug Administration; ©2016. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-updated-fda-review-concludes-use-type-2-diabetes-medicine-pioglitazone

World Health Organization. WHO Pharmaceuticals NEWSLETTER N°3 [Internet]. Switzerland: World Health Organization. ©2019. Available from https://www.who.int/medicines/publications/PharmaNewsletter3-19/en/

Medicines & Healthcare products Regulatory Agency. Denosumab (Xgeva) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation [Internet]. United Kingdom: Medicines & Healthcare products Regulatory Agency; ©2018. Available from https://www.gov.uk/drug-safety-update/denosumab-xgeva-for-giant-cell-tumour-of-bone-risk-of-clinically-significant-hypercalcaemia-following-discontinuation

Pharmaceuticals and Medical Devices Agency. Summary of Investigation Results Denosumab (genetical recombination) (120 mg product) [Internet]. Japan: Pharmaceuticals and Medical Devices Agency; ©2019. Available from https://www.pmda.go.jp/files/000228669.pdf

Agência Nacional de Vigilância Sanitária. Xgeva® (denosumabe) - Nova reação adversa identificada em estudos clínicos. Amgen, 04 de maio de 2017 (Versão 1.3) [Internet]. Brasil: Agência Nacional de Vigilância Sanitária; ©2017. Available from http://portal.anvisa.gov.br/resultado-de-busca?p_p_id=101&p_p_lifecycle=0&p_p_state=maximized&p_p_mode=view&p_p_col_id=column-1&p_p_col_count=1&_101_struts_action=%2Fasset_publisher%2Fview_content&_101_assetEntryId=3409869&_101_type=document&redirect=http%3A%2F%2Fportal.anvisa.gov.br%2Fresultado-de-busca%3Fp_p_id%3D3%26p_p_lifecycle%3D0%26p_p_state%3Dnormal%26p_p_mode%3Dview%26p_p_col_id%3Dcolumn-1%26p_p_col_count%3D1%26_3_groupId%3D0%26_3_keywords%3Ddenosumab%26_3_cur%3D1%26_3_struts_action%3D%252Fsearch%252Fsearch%26_3_format%3D%26_3_formDate%3D1441824476958

Food and Drug Administration. FDA Drug Safety Communication: FDA warns about prescribing and dispensing errors resulting from brand name confusion with antidepressant Brintellix (vortioxetine) and antiplatelet Brilinta (ticagrelor) [Internet]. United States of America: Food and Drug Administration; ©2015. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-prescribing-and-dispensing-errors-resulting-brand-name

World Health Organization. WHO Pharmaceuticals NEWSLETTER N°5 [Internet]. Switzerland: World Health Organization. ©2015. Available from https://www.who.int/medicines/publications/PharmaNewsletter5_15/en/

Colegio de Farmacéuticos de la provincia de Santa Fe. Brintellix® y Brilinta®. Riesgo de error tipo LASA. FDA [Internet]. Argentina: Colegio de Farmacéuticos de la provincia de Santa Fe; ©2015. Available from: https://colfarsfe.org.ar/2016/11/08/brintellix-y-brilinta-riesgo-de-error-tipo-lasa-fda/

Centro Nacional de Documentación e Información de Medicamentos. La FDA cambió de nombre al Brintellix® (vortioxetine) por Trintellix®, para evitar errores de prescripción y dispensación con Brilinta® (ticagrelor) [Internet]. Perú: Centro Nacional de Documentación e Información de Medicamentos; ©2016. Available from http://bvcenadim.digemid.minsa.gob.pe/noticias/278-la-fda-cambio-de-nombre-al-brintellix-vortioxetine-por-trintellix-para-evitar-errores-de-prescripcion-y-dispensacion-con-brilinta-ticagrelor

Ministerio de Salud Costa Rica. Restricciones de uso para reducir riesgo de problemas cardiácos con el uso de ivabradina [Internet]. Costa Rica: Ministerio de Salud; ©2014. Available from https://www.ministeriodesalud.go.cr/index.php/consulta-de-alertas-de-seguridad/2608-17-de-diciembre-de-2014-nueva-informacion-de-seguridad-sobre-ivabradina/file

Therapeutic Goods Administration. Australian Public Assessment Report for Ivabradine [Internet]. Australia: Department of Health; ©2010. Available from https://www.tga.gov.au/sites/default/files/auspar-coralan.pdf

European Medicines Agency. European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan (ivabradine)[Internet]. European Union: European Medicines Agency; ©2014. Available from https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-measures-reduce-risk-heart-problems-corlentorprocoralan

World Health Organization. WHO Pharmaceuticals NEWSLETTER N°4 [Internet]. Switzerland: World Health Organization. ©2015. Available from https://www.who.int/medicines/publications/PharmaNewsletter5_15/en/

Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Ivabradina: información para profesionales de la salud [Internet]. Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos; ©2015. Available from https://app.invima.gov.co/alertas/ckfinder/userfiles/files/INFORMES%20DE%20SEGURIDAD/Medicamentos/2015/Enero/IVABRADINA.pdf.

Medicines & Healthcare products Regulatory Agency. Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects [Internet]. United Kingdom: Medicines & Healthcare productsRegulatory Agency; ©2014. Available from https://www.gov.uk/drug-safety-update/ivabradine-procoralan-in-the-symptomatic-treatment-of-angina-risk-of-cardiac-side-effects

Agencia Española de Medicamentos y Productos Sanitarios. Ivabradina (Corlentor®, Procoralan®): restricciones de uso en pacientes con angina de pecho crónica estable [Internet]. Spain: Agencia Española de Medicamentos y Productos Sanitarios; ©2014. Available from https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2014/ni-muh_fv_17-ivabradina/

Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin [Internet]. United States of America: Food and Drug Administration; ©2016. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes

World Health Organization. WHO Pharmaceuticals NEWSLETTER N°3 [Internet]. Switzerland: World Health Organization. ©2016. Available from https://www.who.int/medicines/publications/PharmaNewsletter3_16/en/

Ministerio de Salud Costa Rica. Nueva información de seguridad con el uso del principio activo saxagliptina [Internet]. Costa Rica: Ministerio de Salud; ©2016. Available from https://www.ministeriodesalud.go.cr/index.php/consulta-de-alertas-de-seguridad/3112-01-de-setiembre-de-2016-nueva-informacion-de-seguridad-con-el-uso-del-principio-activo-saxagliptina/file.

Agência Nacional de Vigilância Sanitária. Onglyza (saxagliptina) y Kombiglyze XR® (saxagliptina y metformina hidrocloruro XR) - Riesgo de insuficiencia cardíaca. AstraZeneca, 8 de junio de 2016 - Cartas a los profesionales de la salud [Internet]. Brasil: Agência Nacional de Vigilância Sanitária; ©2016. Available from http://portal.anvisa.gov.br/cartas-aos-profissionais-de-saude/-/asset_publisher/6Qk8g2SPhy9v/document/id/2824244/rss

Food and Drug Administration. FDA Drug Safety Communication: FDA warns of serious immune system reaction with seizure and mental health medicine lamotrigine (Lamictal) [Internet]. United States of America: Food and Drug Administration; ©2018. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-serious-immune-system-reaction-seizure-and-mental-health

World Health Organization. WHO Pharmaceuticals NEWSLETTER N°3 [Internet]. Switzerland: World Health Organization. ©2018. Available from https://www.who.int/medicines/publications/PharmaNewsletter3_18/en/

Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Información de seguridad sobre el principio activo Lamotrigina y su asociación con reacción grave al sistema inmune [Internet]. Colombia: Instituto Nacional de Vigilancia de Medicamentos y Alimentos; ©2018. Available from https://www.invima.gov.co/documents/20143/851967/INFORME_DE_SEGURIDAD_LAMOTRIGINA.pdf/754fc22a-ee43-0183-c65c-2c9fea6ba4c3.

Centro Nacional de Documentación e Información de Medicamentos. Linfohistiocitosis hemofagocítica, una reacción adversa grave del sistema inmune con lamotrigina [Internet]. Perú: Centro Nacional de Documentación e Información de Medicamentos; ©2018. Available from http://bvcenadim.digemid.minsa.gob.pe/noticias/370-linfohistiocitosis-hemofagocitica-una-reaccion-adversa-grave-del-sistema-inmune-con-lamotrigina

Gustafson A, King C, Rey J. Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity. Pharmacy and Therapeutics. 2013; 38(9): 525-534.

Eisai Co., U.S. FDA approves Belviq XR®, a once-daily formulation of lorcaserin for chronic weight management [Internet]. Japan: Eisai Co.; ©2016. Available from https://www.eisai.com/news/news201652.html#:~:text=Lorcaserin%20was%20approved%20in%20June,or%20greater%20(overweight)%20in%20the

Ministerio de Salud Costa Rica. Medicamento Relucit: Pautas para un Uso Correcto [Internet]. Costa Rica: Ministerio de Salud; ©2018. Available from https://www.ministeriodesalud.go.cr/index.php/alertas/alerta-por-productos-en-el-mercado/3983-12-diciembre-2018-alerta-relucit-con-firmas-escaneadas/file

Food and Drug Administration. Safety clinical trial shows possible increased risk of cancer with weight-loss medicine Belviq, Belviq XR (lorcaserin) [Internet]. United States of America: Food and Drug Administration; ©2020. Available from https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr

Rose MA, Kam PCA. Gabapentin: pharmacology and its use in pain management: Gabapentin. Anaesthesia. 2002; 57: 451–462.

Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel α2–δ (alpha2–delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research. 2007; 73(2): 137–150.

Uptodate. Ranitidine (United States: Withdrawn from market): Drug information [Internet]. Uptodate; ©2020. Available from https://www-uptodate-com.ezproxy.sibdi.ucr.ac.cr/contents/ranitidine-united-states-withdrawn-from-market-drug-information?search=ranitidina&source=panel_search_result&selectedTitle=1~82&usage_type=panel&kp_tab=drug_general&display_rank=1.

Smith U. Pioglitazone: mechanism of action. The International Journal of Clinical Practice. 2001; 121: 13–18.

Food and Drug Administration. Actos (Pioglitazone Hydrochloride) Tablets. Drug Approval Package [Internet]. United States of America: Food and Drug Administration; ©2001. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/021073A_Actos.cfm.

Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. The International Journal of Clinical Practice. 2012: 1139–1146.

Food and Drug Administration. Prolia (denosumab) Injection. Drug Approval Package [Internet]. United States of America: Food and Drug Administration; ©2010. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125320s0000TOC.cfm

Uptodate. Vortioxetine: Drug information [Internet]. Uptodate; ©2020. Available from https://www-uptodate-com.ezproxy.sibdi.ucr.ac.cr/contents/vortioxetine-drug-information?search=vortioxetina&source=panel_search_result&selectedTitle=1~16&usage_type=panel&kp_tab=drug_general&display_rank=1

Food and Drug Administration. FDA Drug Safety Podcast: FDA approves brand name change for antidepressant drug Brintellix (vortioxetine) to avoid confusion with antiplatelet drug Brilinta (ticagrelor) [Internet]. United States of America: Food and Drug Administration; ©2016. Available from https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug-safety-podcast-fda-approves-brand-name-change-antidepressant-drug-brintellix-vortioxetine

Uptodate. Ticagrelor: Drug information [Internet]. Uptodate; ©2020. Available from https://www-uptodate-com.ezproxy.sibdi.ucr.ac.cr/contents/ticagrelor-drug-information?search=ticagrelor&source=panel_search_result&selectedTitle=1~84&usage_type=panel&kp_tab=drug_general&display_rank=1

Food and Drug Administration. Drug Approval Package: Brilinta (ticagrelor) NDA #022433 [Internet]. United States of America: Food and Drug Administration; ©2011. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000TOC.cfm.

Ministerio de Salud Costa Rica. Reporte de productos registrados. Brintellix ® [Internet]. Costa Rica: Ministerio de Salud; ©2019. Available from http://registrelo.go.cr/cfmx/ms/consultasPublicas/productos_Registrados/reporte.cfm.

Ministerio de Salud Costa Rica. Reporte de productos registrados. Brillinta®[Internet]. Costa Rica: Ministerio de Salud; ©2019. Available from http://registrelo.go.cr/cfmx/ms/consultasPublicas/productos_Registrados/reporte.cfm.

Uptodate. Ivabradine: Drug information [Internet]. Uptodate; ©2020. Available from https://www-uptodate-com.ezproxy.sibdi.ucr.ac.cr/contents/ivabradine-drug-information?search=ivabradina&source=panel_search_result&selectedTitle=1~40&usage_type=panel&kp_tab=drug_general&display_rank=1#F27857541

Therapeutic Goods Administration. Ivabradine (Coralan) and cardiovascular events in patients with angina [Internet]. Australia: Department of Health; ©2015. Available from https://www.tga.gov.au/monitoring-communication/ivabradine-coralan-and-cardiovascular-events-patients-angina

Therapeutic Goods Administration. Medicines Safety Update Volume 6 Number 3, June 2015 [Internet]. Australia: Department of Health; ©2015. Available from https://www.tga.gov.au/publication-issue/medicines-safety-update-volume-6-number-3-june-2015

Ministerio de Salud Costa Rica. Reporte de productos registrados. Procoralan® [Internet]. Costa Rica: Ministerio de Salud; ©2017. Available from http://registrelo.go.cr/cfmx/ms/consultasPublicas/productos_Registrados/reporte.cfm.

Uptodate. Saxagliptin: Drug information [Internet]. Uptodate; ©2020. Available from - https://www-uptodate-com.ezproxy.sibdi.ucr.ac.cr/contents/saxagliptin-drug-information?search=saxagliptina&source=search_result&selectedTitle=1~27&usage_type=panel&kp_tab=drug_general&display_rank=1

Uptodate. Alogliptin: Drug information [Internet]. Uptodate; ©2020. Available from https://www-uptodate-com.ezproxy.sibdi.ucr.ac.cr/contents/alogliptin-drug-information?search=Alogliptina&source=search_result&selectedTitle=1~10&usage_type=panel&kp_tab=drug_general&display_rank=1

Food and Drug Administration. Drug Safety and Availability - FDA Drug Safety Communication: FDA to review heart failure risk with diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR) [Internet]. United States of America: Food and Drug Administration; ©2014. Available from https://wayback.archive-it.org/7993/20170112031610/http://www.fda.gov/Drugs/DrugSafety/ucm385287.htm

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. The New England Journal of Medicine. 2013; 369: 1317–1326.

Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, Davidson J, Ohman P, Price DL, Frederich B, Udell JA, Braunwald E, Bhatt DL. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes/Metabolism Research and Review. 2013; 29: 417–426.

White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (examine): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. American Heart Journal. 2011; 162(4): 620-626.e1.

Ministerio de Salud Perú. Revisión de saxagliptina, debido a riego de insuficiencia cardiaca [Internet]. Perú: Ministerio de Salud; ©2014. Available from https://www.gob.pe/institucion/minsa/noticias/66812-revision-de-saxagliptina-debido-a-riego-de-insuficiencia-cardiaca

Uptodate. Lamotrigine: Drug information [Internet]. Uptodate; ©2020. Available from https://www-uptodate-com.ezproxy.sibdi.ucr.ac.cr/contents/lamotrigine-drug-information?search=lamotrigina&source=panel_search_result&selectedTitle=1~126&usage_type=panel&kp_tab=drug_general&display_rank=1

Fischer A. Enfermedades por inmunodeficiencia primaria. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, eds. Harrison Principios de Medicina Interna. 20th ed. New York: McGraw-Hill Education; 2018.

Ministerio de Salud Costa Rica. Lamotrigina. Casos raros de meningitis aséptica [Internet]. Costa Rica: Ministerio de Salud; ©2010. Available from https://ministeriodesalud.go.cr/index.php/consulta-de-alertas-de-seguridad/933-15-de-noviembre-2010-lamotrigina-casos-raros-de-meningitis-aseptica/file.